SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achi ...

Core Insights - Ceribell, Inc. has received FDA 510(k) clearance for its Ceribell Clarity™ algorithm, making it the first AI-powered point-of-care EEG system capable of detecting electrographic seizures in patients aged 1 and older [1][2][3] - The Clarity algorithm is designed to provide comprehensive seizure detection across the largest age range ever addressed by such technology, enhancing the capabilities of hospitals, particularly in emergency departments and ICUs [1][3] - The pediatric clearance was supported by EEG data from over 1,700 patients, marking it as the largest validation dataset for FDA clearance of a seizure detection system [1][3] Company Overview - Ceribell is a medical technology company focused on improving the diagnosis and management of serious neurological conditions through its innovative EEG platform [6] - The Ceribell System combines portable hardware with AI-powered algorithms to enable rapid diagnosis and continuous monitoring of neurological conditions, currently utilized in intensive care units and emergency rooms across the U.S. [6] Industry Impact - The FDA clearance is expected to significantly impact the lives of critically ill children, who are at high risk for preventable brain injury due to seizures [3] - Non-convulsive seizures, which can only be detected through EEG, require prompt identification and treatment to prevent brain injury, highlighting the importance of rapid EEG access [3]